Clinical Trials Logo

Clinical Trial Summary

A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/overexpressed Solid Tumors (ACE-Pan tumor-02)


Clinical Trial Description

The study will enroll subjects with HER2-mutated or HER2-amplified/overexpressed locally advanced or metastatic solid tumor cancers whose prior standard of care therapies have failed. This basket trial will evaluate ARX788 across multiple cancer populations, as defined by HER2 genetic biomarkers ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05041972
Study type Interventional
Source Ambrx, Inc.
Contact
Status Withdrawn
Phase Phase 2
Start date November 5, 2021
Completion date April 20, 2022